KZR-261
A drug being studied in colorectal cancer trials. It appears in 1 clinical trial.
What it is
KZR-261 is an oral small molecule inhibitor designed to target solid tumors including colorectal cancer. This compound is being developed as a targeted therapy for patients with advanced solid malignancies who have limited treatment options. Based on its development profile, KZR-261 appears to be part of a tumor-agnostic approach, meaning it targets specific molecular pathways present across different cancer types rather than being specific to colorectal cancer alone.
How it works
KZR-261 likely functions by inhibiting specific protein kinases or signaling pathways that are critical for tumor cell survival and proliferation. The exact molecular target and mechanism of action have not been fully disclosed in publicly available information, but it appears to interfere with cellular processes that drive cancer growth and metastasis.
Molecular targets
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Trials with this drug
Guides that may help
Written for patients and families, in plain language.